Inc. magazine ranked Velocity Clinical Research 543 on its annual Inc. 5000 list, the most prestigious ranking of the nation’s fastest-growing private companies. Headquartered in Durham, NC, Velocity is the world’s leading integrated site organization with 80 sites worldwide. This is Velocity’s first recognition on the list. Paul Evans, President and CEO of Velocity Clinical … Read more
More than ever, most of us have jobs that involve sitting at a desk for hours on end. The average desk worker in the U.S. is 36 years old and female. While some companies invest in workstation assessments, a lot of us are still working from home where we are less likely to have invested … Read more
Velocity is collaborating with Merck to explore a new way to engage communities about clinical research. Starting this month the Velocity team members are conducting a tour of several Southern California cities, using Merck’s iLab53, a state-of-the-art, modular 39-foot mobile research unit to reach underserved communities. At each stop, the mobile research unit will serve … Read more
At Velocity Clinical Research, we prioritize the voices of clinical trial participants, largely via the Participant Advisory Committee (PAC). Our PAC, which brings together a diverse group of past and current trial participants from across the U.S., offers a unique lens into the clinical research process. In this edition, we’ll unpack key insights gleaned from … Read more
Velocity Clinical Research, the leading integrated site organization for clinical trials, has launched a groundbreaking initiative: Councils to Accelerate Research Excellence (CARE Councils). The CARE Councils underpin Velocity’s dedication to supporting specialty research while providing comprehensive and strategically aligned solutions for Sponsors and CROs. The expert-led CARE Councils bring together seasoned physicians in their areas … Read more
Julio Rosenstock, MD, has his work spotlighted as the feature article on the New England Journal of Medicine’s homepage. Serving as the lead investigator for Novo Nordisk’s ONWARDS 1 program, Dr. Rosenstock has made remarkable strides in exploring what could be the world’s first once-weekly basal insulin. “In ONWARDS 1, insulin icodec allowed people to … Read more
For the team at Velocity Clinical Research in the United Kingdom, clinical trials are first and foremost about building relationships. “I’m really grateful to be involved in clinical trials, because it allows me to develop meaningful connections with people in a way that goes beyond the traditional and [usually] more formal doctor-patient relationship,” says Ahmed … Read more
Velocity Clinical Research (“Velocity”), the leading multi-specialty clinical sites business, and Privia Health (Nasdaq: PRVA), a physician enablement company serving more than 3,700 providers and 4.4 million patients, today announced a partnership to open embedded clinical research sites within Privia’s practice network. The partnership is intended to establish integrated research sites within existing Privia Care … Read more
With nearly three decades as a family physician and almost 25 years as a Principal Investigator (PI), Frank Eder, MD, believes two primary elements are critical for sustained success in clinical research. “You must have a true interest in the research side of it. You have to actually be interested in the science and the … Read more
Julio Rosenstock, MD, and Juan Frias, MD, were featured prominently throughout the American Diabetes Association (ADA) 83rd Scientific Sessions. The prolific researchers also had findings simultaneously published in the New England Journal of Medicine and The Lancet. Dr. Rosenstock is the lead investigator for Novo Nordisk’s ONWARDS 1 program exploring the first investigational once-weekly insulin. … Read more